| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. (IONS) has 21 insiders with recent SEC Form 4 filings, including 0 buys and 19 sells. IONS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 260.3K | $19.75M | - | |
| Dir | 164.0K | $12.45M | -8,000 | |
| VP | 100.3K | $7.61M | - | |
| VP | 83.3K | $6.32M | -60,846 | |
| CFO | 82.7K | $6.27M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sale+OE | 3,162 | $61.02 | $192,942.71 | -17.4% | +34.4% | - | |
| Sep 3, 2025 | Schneider Eugene64 | EVP, Chf Clinical Develop Ofcr | Sale+OE | 19,658 | $60.81 | $1,195,420.87 | -15.1% | +34.4% | - | |
| Sep 3, 2025 | Klein Joseph III60 | Director | Sale+OE | 28,000 | $60.00 | $1,680,000.00 | -100% | +34.4% | - | |
| Sep 3, 2025 | Klein Joseph III60 | Director | Sale+OE | 28,000 | $60.00 | $1,680,000.00 | -100% | +34.4% | - | |
| Sep 3, 2025 | Baroldi Joseph52 | EVP, Chief Business Officer | Sale+OE | 32,800 | $59.34 | $1,946,220.28 | -40.2% | +34.4% | - | |
| Sep 3, 2025 | Loscalzo Joseph | Director | Sale+OE | 16,000 | $60.15 | $962,371.20 | -30.6% | +34.4% | - | |
| Sep 3, 2025 | Wender Joseph H | Director | Sell | 28,000 | $57.58 | $1,612,155.44 | -7.3% | +34.4% | - | |
| Sep 3, 2025 | Wender Joseph H | Director | Sell | 28,000 | $57.58 | $1,612,155.44 | -7.3% | +34.4% | - | |
| Sep 3, 2025 | O'Neil Patrick R.57 | EVP CLO &General Counsel | Sale+OE | 89,900 | $60.03 | $5,396,843.39 | -56.2% | +34.4% | - | |
| Sep 3, 2025 | Bennett C Frank64 | EVP, Chief Scientific Officer | Sale+OE | 38,909 | $59.14 | $2,301,263.58 | -17.0% | +34.4% | - |